What is the role of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in the scenario of new drugs for Multiple Myeloma (MM)

Autores

  • Abrahão Elias Hallack Neto Department of Internal Medicine, University Hospital, Universidade Federal de Juiz de Fora (UFJF), Juiz de Fora, Minas Gerais, Brazil
  • Angelo Maiolino Department of Internal Medicine, University Hospital, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil; Américas Centro de Oncologia Integrado - Title summarized: AHSCT and new drugs for MM

DOI:

https://doi.org/10.46765/2675-374X.2020v1n1p27-29

Resumo

Patients with multiple myeloma (MM) in clinical con­ditions to be referred to autologous hematopoietic stem cell transplantation (AHSCT) generally start therapy with an induction chemotherapy followed by high-dose alkylating and AHSCT. The ideal regimen and the number of pre-AHSCT induction is still a controversial subject, however, opting for at least three to four cycles of chemotherapy including a drug with immunomodulatory action, a protea­some inhibitor, with a corticosteroid, are advised as the first line before AHSCT.

Downloads

Publicado

06/07/2020

Como Citar

Hallack Neto, A. E., & Maiolino, A. (2020). What is the role of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in the scenario of new drugs for Multiple Myeloma (MM). JBMTCT, 1(2), 27–29. https://doi.org/10.46765/2675-374X.2020v1n1p27-29

Artigos mais lidos pelo mesmo(s) autor(es)